摘要
目的：探讨肉毒索A（BTX-A）经尿道尿道外括约肌注射，治疗逼尿肌尿道外括约肌协同失调（DESD）的效果。方法：对11例因患DESD致慢性尿潴留和尿失禁患者，行经尿道尿道外括约肌注射100UBTX—A治疗，对治疗前后的残余尿（PVR）、最大尿道压（MUP）、排尿期最大逼尿肌压（MPdet）和国际尿失禁咨询委员会尿失禁评分调查简表（ICI—Q—SF）评分进行比较。结果：治疗后，MUP、MPdet和ICI-Q-SF显著降低，PVR显著减少。7～30天达最大疗效，单次注射疗效持续2～3个月，重复注射可持续更长时间。无严重不良反应发生。结论：BTX—A尿道外括约肌注射治疗DESD，安全，微创，疗效确切；但需要重复注射维持疗效。
Objective：To evaluate the efficacy of botulinum toxin A （BTX-A） transurethral injection into external urethral sphincter for the treatment of detrusor external sphincter dyssynergia（DESD）. Methods： 11 patients with chronic urinary retention and urinary incontinence caused by DESD were received transurethral injection into the external urethral sphincter of 100U BTX-A. The preoperative and postoperative data of 11 cases were analysed retrospectively. Results：Preoperative post-voiding residual volume （PVR） , the maximal detrusor pressure（MP- det）, the ICI-Q-SF scores and maximal urethral pressure （MUP） decreased significantly one month after treatment （ P 〈0.01） . The maximal efficacy occurred during 7-30 days and lasted for 2-3 months in single injection and for a longer term in repeated injection. There were no side effects. Conclusions： BTX-A injection is a safe, minimally invasive and efficacious treatment for DESD. It is necessary to repeat injections for maintaining the efficacy.
出处
《临床泌尿外科杂志》
2006年第4期255-256,259,共3页
Journal of Clinical Urology
